12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jakafi ruxolitinib regulatory update

Incyte disclosed in its 3Q12 earnings that FDA granted Fast Track designation to ruxolitinib to treat patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. The...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >